
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-14053

MILESTONE SCIENTIFIC INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

13-3545623
(I.R.S. Employer
Identification No.)

220 South Orange Avenue, Livingston, New Jersey 07039
(Address of principal executive offices)

(973) 535-2717
(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

| | | | |
|-------------------------|--|---------------------------|-------------------------------------|
| Large accelerated filer | <input type="checkbox"/> | Accelerated filer | <input type="checkbox"/> |
| Non-accelerated filer | <input type="checkbox"/> (Do not check if a smaller reporting company) | Smaller reporting company | <input checked="" type="checkbox"/> |

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of May 14, 2015, the Issuer had a total of 21,438,093 shares of Common Stock, \$.001 par value outstanding.

MILESTONE SCIENTIFIC INC
TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

| | |
|--|----|
| Item 1. Financial Statements | |
| <u>Condensed Consolidated Balance Sheets</u> | |
| <u>March 31, 2015 (Unaudited) and December 31, 2014 (Audited)</u> | 4 |
| <u>Condensed Consolidated Statements of Operations</u> | |
| <u>Three Months Ended March 31, 2015 and 2014 (Unaudited)</u> | 5 |
| <u>Condensed Consolidated Statement of Changes in Stockholders' Equity</u> | |
| <u>Three Months Ended March 31, 2015 (Unaudited)</u> | 6 |
| <u>Condensed Consolidated Statements of Cash Flows</u> | |
| <u>Three Months Ended March 31, 2015 and 2014 (Unaudited)</u> | 7 |
| <u>Notes to Condensed Consolidated Financial Statements (Unaudited)</u> | 8 |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations.</u> | 16 |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk.</u> | 21 |
| Item 4. <u>Controls and Procedures</u> | 21 |

PART II - OTHER INFORMATION

| | |
|---|----|
| Item 1. <u>Legal Proceedings</u> | 23 |
| Item 1A. <u>Risk Factors</u> | 23 |
| Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 23 |
| Item 3. <u>Defaults Upon Senior Securities</u> | 23 |
| Item 4. <u>Mine Safety Disclosures</u> | 23 |
| Item 5. <u>Other Information</u> | 23 |
| Item 6. <u>Exhibits</u> | 24 |
| <u>SIGNATURES</u> | 25 |

FORWARD-LOOKING STATEMENTS

When used in this Quarterly Report on Form 10-Q, the words “may”, “will”, “should”, “expect”, “believe”, “anticipate”, “continue”, “estimate”, “project”, “intend” and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding events, conditions and financial trends that may affect Milestone’s future plans of operations, business strategy, results of operations and financial condition. Milestone wishes to ensure that such statements are accompanied by meaningful cautionary statements pursuant to the safe harbor established in the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties and the actual results may differ materially from those included within the forward-looking statements as a result of various factors. Such forward-looking statements should, therefore, be considered in light of various important factors, including those set forth herein and others set forth from time to time in Milestone’s reports and registration statements filed with the Securities and Exchange Commission (the “Commission”). Milestone disclaims any intent or obligation to update such forward-looking statements.

MILESTONE SCIENTIFIC INC
CONDENSED CONSOLIDATED BALANCE SHEETS

| | March 31, 2015 (Unaudited) | December 31, 2014 (Audited) |
|---|-------------------------------|--------------------------------|
| <u>ASSETS</u> | | |
| Current Assets: | | |
| Cash and cash equivalents | \$ 9,331,405 | \$ 10,367,993 |
| Accounts receivable, net of allowance for doubtful accounts of \$5,000 as of March 31, 2015 and December 31, 2014 | 1,642,938 | 1,541,478 |
| Due from related party | 184,589 | - |
| Notes Receivable-Milestone Medical Inc | 200,000 | - |
| Inventories | 2,766,013 | 2,497,099 |
| Advances on contracts | 252,306 | 721,197 |
| Prepaid expenses and other current assets | 691,210 | 454,566 |
| Total current assets | 15,068,461 | 15,582,333 |
| Investment in Milestone Medical Inc | 506,947 | 888,720 |
| Investment in Milestone Education LLC | 19,977 | 24,192 |
| Investment in Milestone China | 445,325 | 348,651 |
| Furniture, Fixtures & Equipment net of accumulated depreciation of \$422,001 as of March 31, 2015 and \$416,210 as of December 31, 2014 | 85,448 | 88,818 |
| Patents, net of accumulated amortization of \$594,283 as of March 31, 2015 and \$576,960 as of December 31, 2014 | 512,706 | 530,029 |
| Other assets | 14,685 | 14,685 |
| Total assets | \$ 16,653,549 | \$ 17,477,428 |
| <u>LIABILITIES AND STOCKHOLDERS' EQUITY</u> | | |
| Current Liabilities: | | |
| Accounts payable | \$ 1,229,515 | \$ 1,453,908 |
| Accrued expenses and other payables | 627,192 | 981,168 |
| Total current liabilities | 1,856,707 | 2,435,076 |
| Commitments and Contingencies | | |
| Stockholders' Equity | | |
| Series A Convertible Preferred Stock, par value \$.001, authorized 5,000,000 shares, 7,000 and zero shares issued and outstanding, respectively | 7 | 7 |
| Common stock, par value \$.001; authorized 50,000,000 shares; 21,404,494 shares issued, 974,953 shares to be issued and 21,371,161 shares outstanding as of March 31, 2015. | | |
| 21,404,949 shares issued, 974,953 shares to be issued and 21,371,161 shares outstanding as of December 31, 2014 | 22,380 | 22,380 |
| Additional paid-in capital | 77,586,539 | 77,504,415 |
| Accumulated deficit | (62,386,837) | (61,967,462) |
| Treasury stock, at cost, 33,333 shares | (911,516) | (911,516) |
| Total stockholders' equity | 14,310,573 | 14,647,824 |
| Noncontrolling interest | 486,269 | 394,528 |
| Total Equity | 14,796,842 | 15,042,352 |
| Total liabilities and stockholders' equity | \$ 16,653,549 | \$ 17,477,428 |

See Notes to Condensed Consolidated Financial Statements

MILESTONE SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATION
(Unaudited)

| | Three Months Ended March 31, | |
|---|------------------------------|--------------|
| | 2015 | 2014 |
| Product sales, net | \$ 2,770,204 | \$ 2,620,834 |
| Cost of products sold | 933,148 | 882,997 |
| Gross profit | 1,837,056 | 1,737,837 |
| Selling, general and administrative expenses | 1,898,081 | 1,392,869 |
| Research and development expenses | 10,118 | 15,720 |
| Total operating expenses | 1,908,199 | 1,408,589 |
| (Loss) income from operations | (71,143) | 329,248 |
| Other income (expenses) | | |
| Interest expense | 1,210 | (475) |
| Loss on Earnings from Medical Joint Venture | (450,160) | (130,523) |
| Loss on Earnings from Education Joint Venture | (4,215) | (3,416) |
| Gain on Earnings from China Joint Venture | 96,674 | - |
| Total other expenses, net | (356,491) | (134,414) |
| (Loss) income before provision for income taxes | (427,634) | 194,834 |
| Net loss attributable to the noncontrolling interests | 8,259 | - |
| Net (loss) income attributable to Milestone Scientific Inc | \$ (419,375) | \$ 194,834 |
| Net (loss) income per share applicable to common stockholders - | | |
| Basic | \$ (0.02) | \$ 0.01 |
| Diluted | \$ (0.02) | \$ 0.01 |
| Weighted average shares outstanding and to be issued - | | |
| Basic | 22,346,114 | 17,787,352 |
| Diluted | 22,346,114 | 18,268,814 |

See Notes to Condensed Consolidated Financial Statements

MILESTONE SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
THREE MONTHS ENDED MARCH 31, 2015
(Unaudited)

| | <u>Preferred Stock</u> | | <u>Common Stock</u> | | <u>Additional Paid-in Capital</u> | <u>Accumulated Deficit</u> | <u>Noncontrolling interest</u> | <u>Treasury Stock</u> | <u>Total</u> |
|---|------------------------|---------------|---------------------|-----------------|---|--------------------------------|------------------------------------|---------------------------|---------------------|
| | <u>Shares</u> | <u>Amount</u> | <u>Shares</u> | <u>Amount</u> | | | | | |
| Balance, January 1, 2015 | 7,000 | \$ 7 | 22,379,447 | \$22,380 | \$77,504,415 | \$(61,967,462) | \$ 394,528 | \$(911,516) | \$15,042,352 |
| Stock based compensation | | | - | - | 82,124 | - | - | - | 82,124 |
| Capital contribution from noncontrolling interest | | | - | - | - | - | 100,000 | - | 100,000 |
| Net loss | | | - | - | - | (419,375) | (8,259) | - | (427,634) |
| Balance, March 31, 2015 | <u>7,000</u> | <u>\$ 7</u> | <u>22,379,447</u> | <u>\$22,380</u> | <u>\$77,586,539</u> | <u>\$(62,386,837)</u> | <u>\$ 486,269</u> | <u>\$(911,516)</u> | <u>\$14,796,842</u> |

See Notes to Condensed Consolidated Financial Statements

MILESTONE SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

| | Three Months Ended March 31, | |
|--|------------------------------|--------------|
| | 2015 | 2014 |
| Cash flows from operating activities: | | |
| Net (loss) income | \$ (427,634) | \$ 194,834 |
| Adjustments to reconcile net income net cash provided by (used in) operating activities: | | |
| Depreciation expense | 5,791 | 4,041 |
| Amortization of patents | 17,323 | 19,593 |
| Common stock and options for compensation, consulting and vendor services | 82,124 | 88,052 |
| Loss on Medical Joint Venture | 450,160 | 130,523 |
| Loss on Education Joint Venture | 4,215 | 3,416 |
| Gain on China Joint Venture | (96,674) | - |
| Changes in operating assets and liabilities: | | |
| (Increase) Decrease in accounts receivable | (101,460) | 311,481 |
| (Increase) Decrease in inventories | (268,914) | (423,294) |
| Decrease to advance on contracts | 468,891 | 326,197 |
| (Increase) Decrease to prepaid expenses and other current assets | (236,644) | (50,866) |
| Decrease in accounts payable | (224,393) | (803,233) |
| Increase in Customer Advances | - | 507,345 |
| Decrease in accrued expenses and other payables | (353,976) | (31,121) |
| Net cash (used in) provided by operating activities | (681,191) | 276,968 |
| Cash flows from investing activities: | | |
| Notes receivable to Milestone Medical Inc | (200,000) | - |
| Due from related party | (184,589) | - |
| Investment in Medical joint venture | (68,387) | (58,703) |
| Purchases of property and equipment | (2,421) | (4,616) |
| Net cash (used in) investing activities | (455,397) | (63,319) |
| Cash flows from financing activities: | | |
| Proceeds from exercise of stock options | - | 38,000 |
| Capital Contribution from noncontrolling interest | 100,000 | - |
| Net cash provided by financing activities | 100,000 | 38,000 |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | (1,036,588) | 251,649 |
| Cash and cash equivalents at beginning of period | 10,367,993 | 1,147,198 |
| Cash and cash equivalents at end of period | \$ 9,331,405 | \$ 1,398,847 |
| Supplemental disclosure of cash flow information: | | |
| Shares issued to employees in lieu of cash compensation | \$ - | \$ 11,875 |
| Shares to be issued to directors for prepaid directors' fees | \$ - | \$ 55,200 |

See Notes to Condensed Consolidated Financial Statements

MILESTONE SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

ORGANIZATION, BUSINESS AND BASIS OF PRESENTATION

Milestone Scientific Inc. and subsidiary (collectively "Milestone", "our", "us" or "we") was incorporated in the state of Delaware in August 1989.

The unaudited financial statements of Milestone have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

These unaudited financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2014 included in Milestone's Annual Report on Form 10-K.

In the opinion of management, the accompanying unaudited financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present Milestone's financial position as of March 31, 2015 and the results of its operations for the three months then ended.

The results reported for the three months ended March 31, 2015 are not necessarily indicative of the results of operations which may be expected for a full year.

Milestone has incurred significant operating losses since its inception. Milestone had negative cash flows from operating activities for the three months ending March 31, 2015 of \$681,191 and a positive cash flow of \$276,968 for the three months ended March 31, 2014. At March 31, 2015, Milestone had cash and cash equivalents of \$9,331,405 and a positive working capital of \$13,211,754 as compared to working capital of \$13,147,257 at December 31, 2014. The working capital increased by \$64,497 as compared to December 31, 2014. The change in working capital is primarily due to decrease in cash and cash equivalents offset by a decrease in current liabilities. Milestone's management continues to examine all areas of the business to manage our cash flow. Milestone is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue based upon management's assessment of present contracts and current negotiations and reductions in operating expenses.

As of March 31, 2015, Milestone believes that it has sufficient cash reserves to meet all of its anticipated obligations for the next twelve months. Milestone will continue to manage its cash position while taking strategic steps to expand its business in the medical and dental, business sectors.

NOTE 1 – SUMMARY OF ACCOUNTING POLICIES

Principles of Consolidation

The accompanying consolidated financial statement have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the account of Milestone and its wholly owned subsidiary Wand Dental Inc. Additionally, the consolidated financial statement include the account of Milestone Scientific Advanced Cosmetic System, Inc. ("ACS"), a company that is seventy (70) percent owned by Milestone. The minority interest (thirty percent) in ACS is recorded in the equity section of the consolidated financial statements as noncontrolling interest. All significant intercompany transactions and balances have been eliminated in the consolidation.

Accounts Receivable

The realization of Accounts Receivable current and long-term will have a significant impact on Milestone. The criteria used by management to evaluate the adequacy of the allowance for doubtful accounts included, among others, credit

worthiness of the customer, current trends, prior payment performance, the age of the receivables and Milestone's overall historical experience.

Inventories

Inventory costing, obsolescence and physical control are significant to the on-going operation of the business. Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales.

Investment in Medical Joint Venture

Milestone entered into a Medical Joint Venture with a third party, shareholders of Beijing 3H, and a group of individual investor for the development and commercialization of two medical products. Milestone as of December 31, 2014 own 49.98% of the Medical Joint Venture and have recorded the investment on the equity basis of accounting.

Investment in Milestone China

In July 2014, Milestone agreed to invest \$1.0 million through the contribution of 772 *STA* instruments for a forty percent ownership in Milestone China. 772 *STA* instruments were shipped in 2014 and were recorded at Milestone's cost in the investment account for Milestone China on the balance sheet in the fourth quarter 2014. The distributor will purchase *STA* handpieces on a cash basis as required. Milestone China began operations in July 2014.

Impairment of Long-Lived Assets

The long lived assets of Milestone, principally patents and trademarks are the base features of the business. Milestone reviews long-lived assets for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. The carrying value of the asset is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets.

Revenue Recognition

Revenue from product sales is recognized net of discounts and allowances to domestic distributors on the date of shipment for essentially all shipments, since the shipment terms are FOB warehouse. Milestone will recognize revenue on date of arrival of the goods at the customer's location where shipments are FOB destination. Shipments to international distributors are FOB the warehouse and revenue is therefore recognized on shipment. In both cases the price to the buyer is fixed and the collectability is reasonably assured. Further, Milestone has no obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Milestone's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.

Recent Accounting Pronouncements

Standards Board issued a new standard ASU No. 2014-09, "Revenue from Contracts with Customers." Under ASU 2014-09 recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new standard will be effective for the Company January 1, 2017. The Company is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows.

On February 18, 2015, the Financial Accounting Standards Board issued a new standard ASU No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis." The new standard affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. It will be effective for the Company on January 1, 2016. The Company is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows.

NOTE – 2 BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE

Milestone presents “basic” and “fully diluted” earnings (loss) per common share applicable to common stockholders, and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of FASB ASC Topic 260. Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is similar to that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and warrants were issued during the period. (Fully diluted shares are only calculated if there is a net income.)

For the quarters ending March 31, 2014, Milestone calculated basic and fully diluted earnings per common share as described in the previous paragraph.

NOTE – 3 ACCOUNTS RECEIVABLE

Milestone sells a significant amount of its product on credit terms to its major distributors. Milestone estimates losses from the inability of its customers to make payments on amounts billed. A majority of credit sales are due within ninety days from invoicing.

NOTE – 4 INVESTMENT IN UNCONSOLIDATED SUBSIDIARIES

Milestone Medical Inc

In March 2011, Milestone entered into an agreement with shareholders of Beijing 3H Scientific Technology Co., Ltd (“Beijing 3H”), a People’s Republic of China (“PRC”) Company, and a group of other investors, to establish a medical joint venture entity in the PRC to develop intra-articular and epidural drug delivery instruments utilizing Milestone’s patented *CompuFlo* technology. Shareholders of Beijing 3H and other investors contributed \$1.5 million and Milestone contributed an exclusive worldwide royalty-free license to use CompuFlo technology to this medical joint venture entity.

Milestone, with the consent of Beijing 3H, organized a domestic research and development corporation now known as Milestone Medical Inc. (“Milestone Medical”) to which the principal shareholders of Beijing 3H and a group of other investors completed a capital contribution of \$1,500,000. Milestone Medical was initially owned fifty percent by shareholders of Beijing 3H and a group of other investors, and fifty percent by Milestone. Milestone Medical had a remaining net book value of approximately \$507,000 at March 31, 2015. Milestone has accounted for its investment in Milestone Medical using the equity method of accounting. Further, Milestone was authorized by the Milestone Medical to manage and oversee the development of the epidural and intra-articular instruments. In connection with this authorization, Milestone also entered into an agreement with a significant vendor to develop these two instruments.

Milestone has distribution responsibility in the U.S. and Canada. Beijing 3H was responsible for distribution in Macao, Hong Kong and other regions of Asia. Milestone Medical will distribute the epidural instruments in the PRC. In the rest of the world, responsibilities are shared by Milestone and Beijing 3H.

In July 2013, Milestone entered a strategic partnership with the largest provider of specialty sales and distribution solutions for healthcare in the United States. During the three year strategic partnership, the distributor will hold the exclusive rights to market, resell, label and distribute Milestone’s *CompuFlo* injection technology for use in epidural applications for childbirth and other pain management needs in hospitals in the U.S. This agreement will begin after FDA approval.

In the fourth quarter of 2013, Milestone Medical issued 2 million shares of its common stock in a private placement offering at \$1.50 per share (\$3.0 million) in Poland. As a result of this sale, Milestone Medical received net proceeds of \$2,363,000. The effect of this private placement was to reduce Milestone’s percentage of ownership of Milestone Medical from 50% to 45.5% (post transaction). Consistent with the equity method of account, the ownership percentage is treated as if the decreased percentage of ownership was the result of the sale of these shares. As a result, Milestone recorded in the fourth quarter of 2013, a \$1,363,650 gain on dilutive effect of the sale of equity in Milestone Medical.

In the fourth quarter of 2014, Milestone purchased an additional 995,000 shares of Milestone Medical from another shareholder for \$447,750 (\$0.45 per share), which increased its percentage of ownership to 49.98% of Milestone Medical. Also in the fourth quarter of 2014, Milestone Medical terminated its distribution agreement with Beijing 3H and contracted with Milestone China (defined below) to become its new distributor in Asia for both the epidural and intra-articular instruments. Milestone China is forty percent owned by Milestone.

Milestone recorded a loss on its investment in Milestone Medical of \$450,160 and \$130,523 for the three months ended March 31, 2015 and 2014, respectively. The losses described represent 49.98% and 45.5% of the applicable losses reported by Milestone Medical during the three months ended March 31, 2015 and 2014, respectively. Milestone utilizes the equity method of accounting to recognize its financial results of the joint venture.

Milestone expensed \$45,000 and \$39,153 on behalf of the Milestone Medical for the three months ended March 31, 2015 and 2014, respectively, for legal expenses related to seeking U.S. Food and Drug Administration ("FDA") marketing clearance for the epidural and intra-articular devices under section 510k. As part of the joint venture agreement, Milestone is to pay all fees related to the FDA clearance process.

Milestone had an investment in Milestone Medical of \$506,947 and \$852,295 as of March 31, 2015 and 2014, respectively, and there are no remaining suspended losses.

On July 1, 2013, Milestone and Milestone Medical signed an agreement for the reimbursement of specific expenses incurred by Milestone specifically for the benefit of Milestone Medical. The expenses related to the agreement that have not been paid are \$162,214 and \$48,641 as of March 31, 2015 and 2014, respectively. This includes \$246,505 and \$24,553 of charges for the three months ended March 31, 2015 and 2014, respectively.

Milestone Medical is a Development Stage Company and does not have revenues at this time.

Milestone Education LLC.

The Education Joint Venture has been providing training and education to our dentists throughout the world. Milestone accounted for its investment in the Education Joint Venture using the equity method of accounting. The Education Joint Venture incurred a loss of \$4,215 and \$3,415 for the three months ended March 31, 2015 and 2014, respectively. Fifty percent of these losses were recorded in the consolidated statements of operations.

Milestone China Inc

In June 2014, Milestone agreed to invest \$1.0 million through the contribution of 772 *STA* instruments (at a distributor price of approximately \$1,295 per instrument) for a forty percent ownership in Milestone China Inc., a Hong Kong based medical and dental distribution company ("Milestone China"). The instruments will be shipped to the distributors over a period of two years. Milestone China will purchase *STA* handpieces on a cash basis as required. 772 *STA* instruments were shipped in 2014 and are recorded at Milestone's cost in the investment account for Milestone China on the balance sheet at December 31, 2014. Milestone China did not begin operations until July 2014. Milestone Scientific had recognized income of \$96,674, which is forty (40) percent of the \$241,696 net income recognized by Milestone China, for the three months ended March 31, 2015, which was recorded in the condensed consolidated statement of operations for the three months ended March 31, 2015. Milestone's investment in Milestone China is \$445,325 and \$348,651 as of March 31, 2015 and December 31, 2014, respectively.

NOTE – 5 STOCK OPTION PLANS

A summary of option activity for employees under the plans and changes during the three months ended March 31, 2015, is presented below:

| | Number of Options | Weighted Averaged Exercise Price \$ | Weighted Average Remaining Contractual Life (Years) | Aggregate Intrinsic Options Value \$ |
|------------------------------|----------------------------------|--|--|---|
| Outstanding, January 1, 2015 | 1,472,130 | 1.33 | 3.23 | 1,430,231 |
| Granted | 100,000 | 2.50 | - | - |
| Exercised | - | - | - | - |
| Forfeited or expired | - | - | - | - |
| Outstanding, March 31, 2015 | 1,572,130 | 1.40 | 3.10 | 2,460,722 |
| Exercisable, March 31, 2015 | 1,058,418 | 1.09 | 2.49 | 2,019,427 |

Milestone recognizes stock compensation expense on a straight line basis over the requisite service period. During the three months ended March 31, 2015, Milestone recognized \$82,124 of total stock compensation cost. During the three months ended March 31, 2014, Milestone recognized \$39,877 of total stock compensation cost. As of March 31, 2015 and March 31, 2014, there was \$949,780 and \$357,790, respectively, of total unrecognized compensation cost related to non-vested options which Milestone expects to recognize over a weighted average period of 3.10 years and 2.5 years at March 31, 2015 and 2014, respectively. A six percent rate of forfeitures is assumed in the calculation of the compensation cost for the period in 2015 and 2014.

Expected volatilities are based on historical volatility of Milestone's common stock over a period commensurate with the anticipated term. Milestone uses historical data to estimate option exercise and employee termination within the valuation model.

A summary of option activity for non-employees under the plans and changes during the three months ended March 31, 2015, is presented below:

| | Number of Options | Weighted Averaged Exercise Price \$ | Weighted Average Remaining Contractual Life (Years) | Aggregate Intrinsic Options Value \$ |
|------------------------------|----------------------------------|--|--|---|
| Outstanding, January 1, 2015 | 16,666 | 1.27 | 0.62 | 17,166 |
| Granted | - | - | - | - |
| Exercised | - | - | - | - |
| Forfeited or expired | - | - | - | - |
| Outstanding, March 31, 2015 | 16,666 | 1.27 | 0.37 | 28,832 |
| Exercisable, March 31, 2015 | 16,666 | 1.27 | 0.37 | 28,832 |

During the three months ended March 31, 2015 and March 31, 2014, Milestone had no expenses related to non-employee options that vested during the period. There was no unrecognized compensation cost related to non-vested options as of March 31, 2015. A six percent rate of forfeitures is assumed in the calculation of the compensation cost for the period.

In accordance with the provisions of FASB ASC 505-50-15, all other issuances of common stock, stock options or other equity instruments to non-employees as consideration for goods or services received by Milestone are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of any options or similar equity instruments issued is estimated based on the Black-Scholes option-pricing model and the assumption that all of the options or other equity instruments will ultimately vest. Such fair value is measured as of an appropriate date pursuant to the guidance, (generally, the earlier of the date the other party becomes committed to provide goods or services or the date of performance by the other party is complete) and capitalized or expensed as if Milestone had paid cash for the goods or services.

NOTE – 6 CONCENTRATION OF CREDIT RISK

Milestone's consolidated financial instruments that are exposed to concentrations of credit risk consist primarily of cash and trade accounts receivable, and advances on contracts. Milestone places its cash and cash equivalents with large financial institutions. At times, such investments may be in excess of the Federal Deposit Insurance Corporation insurance limit. Milestone has not experienced any losses in such accounts and believes it is not exposed to any significant credit risks. Financial instruments which potentially subject Milestone to credit risk consist principally of trade accounts receivable, as Milestone does not require collateral or other security to support customer receivables, and advances on contracts. Milestone entered into a purchase agreement with a vendor to supply Milestone with 12,000 *STA Instruments* (104 instruments are remaining on the purchase order as of March 31, 2015). Milestone does not believe that significant credit risk exists with respect to this advance to the contract manufacturer.

Milestone closely monitors the extension of credit to its customers while maintaining allowances, if necessary, for potential credit losses. On a periodic basis, Milestone evaluates its accounts receivable and establishes an allowance for doubtful accounts, based on a history of past write-offs and collections and current credit conditions. Management has provided a reserve that it believes is sufficient to record accounts receivable at net realizable value as of March 31, 2015 and December 31, 2014.

NOTE – 7 ADVANCES ON CONTRACTS

The advances on contracts represent funding of future *STA* inventory purchases. The balance of the advances as of March 31, 2015 and December 31, 2014 is \$252,306 and \$721,197, respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory.

NOTE – 8 INCOME TAXES

Milestone's expected federal and state income tax liability and benefit computed at the statutory rate (40%) on the pre-tax income for the quarters ending March 31, 2015 and 2014, amounted to a liability of approximately \$39,000 and \$151,000, respectively. Such expense was recognized in the accompanying consolidated financial statements as of March 31, 2015 and 2014 with recognition of a net operating loss carryforward. Due to Milestone's history of past operating losses, which required a full valuation allowances for all of Milestone's deferred tax assets at March 31, 2015 and 2014, no recognition was given to the utilization of the remaining net operating loss carryforwards.

NOTE – 9 COMMON STOCK ISSUANCES

During the three months ended March 31, 2015, Milestone did not issue any shares. During the three months ended March 31, 2014, Milestone issued 6,986 shares of common stock valued at \$11,875 for payment of employee compensation. In addition, 95,000 shares are to be issued on the exercised of certain stock options at a price of \$0.40 per share during the quarter ending March 31, 2014. Milestone issued 13,939 shares of common stock valued at \$22,500 for payment of consulting services. In the first quarter of 2014, Milestone's to be issued shares for the Board are 30,000 valued at \$55,200 for their Directors' compensation. Additionally, Milestone raised \$10 million (\$9.4 million net) on the sale of common and convertible preferred stock in May 2014.

NOTE – 10 PREFERRED STOCK ISSUANCE

In May 2014, Milestone completed a \$10 million private placement pursuant to which it raised \$3 million, from the sales of 2 million shares of common stock at \$1.50 per share and \$7 million from the sale of 7,000 shares of Series A Convertible Preferred Stock (the "Series A Stock"), with a stated value of \$1,000 per share. The Series A Stock votes together with the Common Stock on an as converted basis and as a single class, except that such shares have class voting rights as to amendments to the Certificate of Incorporation adversely affecting the Series A Stock, increases in the number

of authorized shares in that Series, issuance of additional shares of Series A Stock, increases in the size of the board prior to the time the holders of the Series A Stock no longer have a right to nominate a designee for election to the board or issuance of “senior stock” or “parity stock.” The Series A Stock is also entitled to a liquidation preference equal to the greater of 100% of its \$1,000 per share stated value or the amount the Series A Stock would receive on conversion into common stock and is convertible into common stock at \$2.545 per share at the option of the holder or mandatorily convertible at this price on May 14, 2019, unless certain “threshold” prices have not been achieved prior to that date.

NOTE – 11 RELATED PARTY

Milestone has a manufacturing agreement with a related party. The related party manufactures products under specific purchase orders but without minimum purchase commitments. Milestone purchased \$617,602 and \$824,574 from the supplier for the three months ended March 31, 2015 and 2014, respectively. Milestone owed \$523,576 and \$455,574 to this supplier as of March 31, 2015 and December 31, 2014, respectively.

On July 1, 2013, Milestone and Milestone Medical signed an agreement for the reimbursement of specific expenses incurred by Milestone specifically for the benefit of Milestone Medical. At March 31, 2015, the expenses due from Milestone Medical are \$184,589.

In December 2014 Milestone entered into a bridge financing to Milestone Medical while waiting approval of the capital raise, Milestone Scientific (49.9% owners) entered into a line of credit agreement which allows Milestone Medical to withdraw funds from Scientific up to \$2 million through January 2016, if needed to assist in paying for the capital raise. The loan provides for interest charge at a rate of 3.25% per annual, the prime rate at the inception of the line of credit. The agreement terminates at April 15, 2016. \$200,000 was borrowed by Milestone Medical at March 31, 2015 and is recognized as notes receivable on the condensed consolidated balance sheet.

NOTE – 12 SIGNIFICANT CUSTOMERS & GEOGRAPHICAL INFORMATION

Milestone had two customers (distributors) for the three months ended March 31, 2015, that had approximately 42%, (27% and 14%), of its net product sales and three customers (distributors) that had approximately 57%, (21%, 24% and 12%), of its net product sales for three months ended March 31, 2014. Milestone had gross accounts receivable for two major customers that amounted to \$801,448, (\$412,648 and \$388,880), representing 49%, (29% and 28%), as of March 31, 2015 and gross accounts receivable for one major customer that amounted to \$732,762, or 48% as of December 31, 2014, respectively.

Milestone’s sales by product and by geographical region are as follows:

| | Three Months Ended March 31, | |
|---------------|------------------------------|---------------------|
| | 2015 | 2014 |
| Instruments | \$ 1,126,579 | \$ 840,981 |
| Handpieces | 1,646,514 | 1,733,217 |
| Other | (2,890) | 46,636 |
| | <u>\$ 2,770,204</u> | <u>\$ 2,620,834</u> |
| United States | \$ 867,560 | \$ 1,213,643 |
| Canada | 15,977 | 24,736 |
| Other Foreign | 1,886,666 | 1,382,455 |
| | <u>\$ 2,770,204</u> | <u>\$ 2,620,834</u> |

NOTE – 13 PENSION PLANS

Milestone has a defined contribution plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone does not contribute to this plan but does pay the administrative costs of the plan, which are not significant.

In March 2014, the Board of Directors approved the Compensation Committee's request to amend the Chief Executive Officer of Milestone's employment agreement to provide benefits to make payments of \$203,111 per year for five years to the Executive, or as he directs such payments to a third party, to fund his acquisition of, or contribution to an annuity, pension, or deferred distribution plan or for an investment for the Executive and his family. For the quarters ended March 31, 2015 and 2014, approximately \$51,000 and \$17,000, respectively, was charged to expenses for this commitment. .

NOTE – 14 COMMITMENTS AND OTHER

Milestone has informal arrangements for the manufacture of its products. *STA*, single tooth anesthesia, *CompuDent* and *CompuMed* instruments are manufactured for Milestone by Tricor Systems, Inc. pursuant to specific purchase orders. The *STA* and *The Wand Handpiece with Needle* is supplied to Milestone by a contractor in the United States, which arranges for its manufacture with two factories in China.

The termination of the manufacturing relationship with any of the above manufacturers could have a material adverse effect on Milestone's ability to produce and sell its products. Although alternate sources of supply exist and new manufacturing relationships could be established, Milestone would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, whether or not as a result of termination of such a relationship, would adversely affect Milestone.

The technology underlying the *SafetyWand* and *CompuFlo*, and an improvement to the controls for *CompuDent* were developed by the Director of Clinical Affairs and assigned to us. Milestone purchased this technology pursuant to an agreement dated January 1, 2005. The Director will receive additional payments of 2.5% of the total sales of products using certain of these technologies, and 5% of the total sales of products using certain other of the technologies. In addition, the Director is granted, pursuant to the agreement, an option to purchase, at fair market value on the date of the grant, 8,333 shares of the common stock upon the issuance of each additional patent relating to these technologies. If products produced by third parties use any of these technologies (under license from us) then the Director will receive the corresponding percentage of the consideration received by Milestone for such sale or license. Milestone expensed the Director's royalty fees of \$111,484 and \$104,197 for the three months ended March 31, 2015 and 2014, respectively. Additionally, Milestone expensed consulting fees to the Director of \$23,400 and \$14,300 for the three months ended March 31, 2015 and 2014, respectively.

In January 2010, Milestone issued a purchase order to Tricor Systems Inc for the purchase of 12,000 *STA Instruments* to be delivered over the next three years. The purchase order is for \$5,261,640. Consequently, advances on contracts have been classified as current at March 31, 2015 and 2014.

In August 2013, a shareholder of Milestone entered a three year agreement with Milestone to provide financial and business strategic services. The fee for these services are \$100,000 annually.

Subsequent Events

The Company has evaluated subsequent events through May 14, 2015 and have determined that there are no events to be disclosed.

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussions of our financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this Form 10-Q. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements.

OVERVIEW

In 2015, Milestone remains focused on advancing efforts to achieve our two primary objectives; those being:

- Enhancing our global reach by partnering with distribution companies in the medical sector and
- Optimizing our tactical approach to product sales and marketing in order to materially increase penetration of the global dental and medical markets with our proprietary, patented Computer-Controlled Local Anesthesia Delivery (C-CLAD) solution, the *STA Single Tooth Anesthesia Instrument* (*STA Instrument*)

STA Instrument Growth

Since its market introduction in early 2007, the *STA Instrument* and a prior computerized controlled local anesthesia delivery product have been used to deliver over 49 million safe, effective and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the *STA Instrument* is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide.

Global Distribution Network

United States and Canadian Market

In August 2013, Milestone entered an exclusive distributor agreement (beginning October 1, 2013), with Henry Schein, for the sale and distribution of the *CompuDent* handpieces in the United States and Canada.

In July 2013, Milestone entered a strategic partnership with the largest provider of specialty sales and distribution solutions for healthcare. Pursuant to the strategic partnership, the distributor will hold, for a period of three years with the FDA market, the exclusive rights to market, resell, label and distribute Milestone's *CompuFlo* injection technology for use in epidural applications for childbirth and other pain management needs in the U.S. hospital sector.

In November 2012, Milestone entered an exclusive distribution and marketing agreement with a well-known U.S. domestic manufacturer and distributor, for the sale and distribution of the *STA instruments* and *handpieces* in United States and Canada.

International Market

On the global front, we also have granted exclusive marketing and distribution rights for the *STA Instrument* to select dental suppliers in various international regions in Asia, Africa, South America and Europe. They include Istrodent in South Africa and Unident in the Scandinavian countries of Denmark, Sweden, Norway and Iceland.

In early October 2012, the State Food and Drug Administration (SFDA) of the People's Republic of China approved Milestone's *Single Tooth Anesthesia System*® (*STA System*). In May 2014, the CFDA, (previously the SFDA), granted registration approval of the *STA* handpieces in China.

Shortly before the end of the second quarter 2009, we announced that we were refining our international marketing strategy to gain greater access to and penetration of the international dental markets for the *STA Instrument*, *CompuDent* and related disposable handpieces. The new sales strategy provides for increasing hands-on oversight and support of our existing international distribution network, while also attracting new distributors throughout Europe, Asia and South America. To assist in this endeavor, Milestone added in the spring of 2010 an International Sales Director to focus on the growth of our products outside the USA and Canada.

In March 2011, we entered into a definitive joint venture agreement with shareholders of Beijing 3H (Heart-Help-Health) Scientific Technology Co., Ltd. (Beijing 3H) and a group of individual investors for the development, commercialization, manufacture and marketing of epidural and intra-articular injection medical instruments. In the fourth quarter of 2014, the Company purchased an additional 995,000 shares from a former shareholder in Milestone Medical Inc for \$447,750 (\$0.45 per share). After this purchase, the Company owned 49.98% of Milestone Medical. At the same time, Milestone Medical Inc terminated its distribution agreement with Beijing 3H. Milestone Medical Inc contracted with Milestone China to become the new distributor in Asia for both the epidural and intra-articular instruments. The Company owns forty percent of Milestone China Ltd.

Milestone contributed an exclusive worldwide royalty-free license to use its patents as they pertain to these two instruments and disposables only to the Medical Joint Venture. Shareholders Beijing 3H and a group of individual investors contributed \$1.5 million to the joint venture to enable the joint venture to design and develop two commercial instruments and related disposables using Milestone's *CompuFlo*® technology. Milestone has distribution responsibility in the U.S. and Canada while Beijing 3H had distribution responsibility exclusively in the People's Republic of China, Macao, Hong Kong and other regions of Asia. In the third quarter of 2014, a shareholder of Beijing 3H sold his interest in Milestone Medical Inc. and the agreement with Beijing 3H to distribute said instruments in Asia was terminated. Milestone China (40% owned by Milestone) signed distributor agreement with Milestone to distribute Milestone Medical Inc. instruments in Asia. As of March 31, 2015, the Medical Joint Venture and the development project is ongoing and nearing the completion of the two medical instruments. In fact, in September 2014 Milestone Medical Inc. received CE clearance to distribute their instruments in European Community (EU). Milestone is actively pursuing Medical distributors for the instrument in the EU community. Milestone Medical Inc signed a distribution agreement in March 2015, with a Polish Medical distributor for the distribution of the epidural instrument which began in April 2015.

In November 2013, Milestone Medical Inc., issued 2 million shares of its common stock at \$1.50 per share, totaling (\$3.0 million), in a private placement in Poland. The consummation of the private placement provided for the admission of the Milestone Medical Inc. common stock for trading on a platform maintained by the Warsaw Stock Exchange. As a result of this transaction, Milestone owned approximately forty-five (45.5%) percent (post-transaction) of Milestone Medical Inc. and Milestone recorded a \$1,363,650 gain on the dilutive effect of these additional shares issued by Milestone Medical Inc. In the fourth quarter of 2014, Milestone purchased an additional 995,000 shares of Milestone Medical Inc. from a founding shareholder. As a result, Milestone's percentage of ownership was increased to 49.98% of Milestone Medical Inc. at December 31, 2014.

In late June 2014, Milestone agreed to invest \$1 million for a 40% ownership in Milestone China Inc., a Hong Kong organized medical and dental distribution company ("Milestone China"). Milestone contributed 772 *STA* instruments to this entity. Additional handpieces will be purchased for cash as required. We expect Milestone China to positively impact dental and future medical business in PRC and other parts of Asia. Milestone China did not begin operations until July 2014 and the first shipment of 300 *STA* instruments occurred in July 2014. Milestone recorded this investment under the equity method of accounting. The remaining 472 *STA* instruments were shipped in December 2014 by Milestone to Milestone China with delivery in January 2015.

Segmented Sales Performance

The following table shows a breakdown of Milestone's product sales (net), domestically and internationally, by product category, and the percentage of product sales (net) by each product category:

Three Months Ended March 31,

| | 2015 | | 2014 | |
|--|---------------------|----------------|---------------------|----------------|
| DOMESTIC | | | | |
| Instruments | \$ 448,965 | 51.8 % | \$ 158,708 | 13.1 % |
| Handpieces | 432,062 | 49.8 % | 1,025,493 | 84.5 % |
| Other | (13,467) | -1.6 % | 29,442 | 2.4 % |
| Total Domestic | <u>867,560</u> | <u>100.0 %</u> | <u>1,213,643</u> | <u>100.0 %</u> |
| INTERNATIONAL | | | | |
| Instruments | \$ 677,614 | 35.6 % | \$ 682,273 | 48.5 % |
| Handpieces | 1,214,452 | 63.8 % | 707,725 | 50.3 % |
| Other | 10,578 | 0.6 % | 17,193 | 1.2 % |
| Total International | <u>1,902,644</u> | <u>100.0 %</u> | <u>1,407,191</u> | <u>100.0 %</u> |
| DOMESTIC/INTERNATIONAL ANALYSIS | | | | |
| Domestic | \$ 867,560 | 31.3 % | \$ 1,213,643 | 46.3 % |
| International | 1,902,644 | 68.7 % | 1,407,191 | 53.7 % |
| Total Product Sales | <u>\$ 2,770,204</u> | <u>100.0 %</u> | <u>\$ 2,620,834</u> | <u>100.0 %</u> |

We earned gross profits of 66% for the three months ended March 31, 2015 and 2014. However, the revenues and related gross profits have not been sufficient to support overhead, new product introduction and research and development expenses. Although Milestone anticipates expending funds for research and development in 2015, these amounts will vary based on the operating results for each quarter. Milestone has incurred annual operating losses and negative cash flows from operating activities since its inception, except for 2013. Milestone, at March 31, 2015, as a result of \$10 million capital raise (\$9.4 million net cash) in May 2014, has sufficient cash reserves to meet all of its anticipated obligations for at least the next twelve months. Milestone is actively pursuing the continued generation of positive cash flows from operating activities through increase in revenue, assessment of current contracts and current negotiations.

In 2015, Milestone plans to further support increased sales and marketing activity through our current distributors and through newly appointed distributors of the *STA* instruments and handpieces in the international market. In the U.S. and Canada, Milestone will continue the utilization of independent hygienists' for training individual practitioners and group practices domestically, refined and directed advertising to dental professionals, and support and broaden our global distribution network.

Milestone announced the formation of a strategic alliance, whereby a third party distributor will serve as the exclusive distributor of Milestone's *Single Tooth Anesthesia System*® (Wand *STA* System) and all related disposable items in the United States and Canada, beginning November 15, 2012. Additionally, the third party distributor will initiate a marketing campaign to drive sales in these territories.

In August 2013, Milestone appointed Henry Schein as its exclusive distributor in the USA and Canada for the *CompuDent* handpieces.

Summary of Significant Accounting Policies, Judgments and Estimates

Milestone's discussion and analysis of the financial condition and results of operations are based upon its financial statements, which have been prepared in accordance with accounting principles, generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, Milestone evaluates its estimates, including those related to accounts receivable, inventories, stock-based compensation and contingencies. Milestone bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions.

While significant accounting policies are more fully described in Note S to the financial statements included elsewhere in this report, Milestone believes that the following accounting policies and significant judgments and estimates are most critical in understanding and evaluating the reported financial results.

Treasury Bills

The fair values of Milestone marketable securities are determined in accordance with GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by GAAP.

Accounts Receivable

The realization of Accounts Receivable current and long-term will have a significant impact on Milestone. The criteria used by management to evaluate the adequacy of the allowance for doubtful accounts included, among others, credit worthiness of the customer, current trends, prior payment performance, the age of the receivables and Milestone's overall historical experience.

Inventories

Inventory costing, obsolescence and physical control are significant to the on-going operation of the business. Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales.

Investment in Medical Joint Venture

Milestone entered into a Medical Joint Venture with a third party and a group of individual investor for the development and commercialization of two medical products. Milestone as of December 31, 2014 own 49.98% of the Medical Joint Venture and have recorded the investment on the equity basis of accounting. Milestone's proportionate share of expenses incurred by the Medical Joint Venture will be charged to the Statement of Operations on a periodic basis.

Investment in Milestone China

In July 2014, Milestone agreed to invest \$1.0 million through the contribution of 772 *STA* instruments for a forty percent ownership in Milestone China. 772 *STA* instruments were shipped in 2014 and were recorded at Milestone's cost in the investment account for Milestone China on the Balance Sheet in the fourth quarter 2014. The distributor will purchase *STA* handpieces on a cash basis as required. Milestone China began operations in July 2014.

Impairment of Long-Lived Assets

The long lived assets of Milestone, principally patents and trademarks are the base features of the business. Milestone reviews long-lived assets for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. The carrying value of the asset is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets.

Revenue Recognition

Revenue from product sales is recognized net of discounts and allowances to domestic distributors on the date of shipment for essentially all shipments, since the shipment terms are FOB warehouse. Milestone will recognize revenue on date of arrival of the goods at the customer's location where shipments are FOB destination. Shipments to international distributors are FOB the warehouse and revenue is therefore recognized on shipment. In both cases the price to the buyer is fixed and the collectability is reasonably assured. Further, Milestone has no obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Milestone's only obligation after sale is the

normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.

Results of Operations

The consolidated results of operations for the three months ended March 31, 2015 compared to the same three month period in 2014 reflect our focus and development on the *Wand/STA Instrument*, as well as continuing efforts on identifying collaborative partners which will allow for new product development utilizing our *CompuFlo* technology.

The following table sets forth, for the periods presented, the statement of operations data as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results.

| | Three Months Ended March 31 | | | |
|--|-----------------------------|-------|--------------|-------|
| | 2015 | | 2014 | |
| Total revenue | \$ 2,770,204 | 100 % | \$ 2,620,834 | 100 % |
| Cost of products sold | 933,148 | 34 % | 882,997 | 34 % |
| Gross Profit | 1,837,056 | 66 % | 1,737,837 | 66 % |
| Selling, general and administrative expenses | 1,898,081 | 69 % | 1,392,869 | 50 % |
| Research and development expenses | 10,118 | 0 % | 15,720 | 1 % |
| Operating expenses | 1,908,199 | 69 % | 1,408,589 | 51 % |
| (Loss) income from operations | (71,143) | -3 % | 329,248 | 12 % |
| Total other income (expense) before provision for income taxes | (356,491) | -13 % | (134,414) | -5 % |
| Net (loss) income | (427,634) | -15 % | 194,834 | 7 % |
| Less: Net loss attributable to the noncontrolling interests | 8,259 | 0 % | - | 0 % |
| Net (loss) income attributable to Milestone Scientific Inc. | \$ (419,375) | -15 % | \$ 194,834 | 7 % |

Three months ended March 31, 2015 compared to three months ended March 31, 2014

Total product sales for the three months ended March 31, 2015 and 2014 were \$2,770,204 and \$2,620,834, respectively. The total increase in product sales of \$149,370 or 6%, in 2015 from 2014 is principally the result of increase in international revenues. Domestic instruments sales increased by \$290,257 in 2015 from 2014. In the domestic market, the total handpiece sales decreased by \$593,431 or 58% in 2015 over 2014. This decrease in domestic handpiece sales is not identified as a continuing issue. On the international front, handpiece sales increased by \$506,728 or 72% due to an increase in *Wand* handpieces sales of \$419,601 in 2015 over 2014. *STA* handpiece sales increased by \$87,127 or 67% for the first quarter 2015 over 2014. The sales of *Wand Plus Instruments* to the European community ceased in 2012 due to a change in the regulations. The *Wand Plus* users in Europe will continue to own, utilize and purchase the handpieces.

Cost of products sold for the three months ended March 31, 2015 and 2014 were \$933,148 and \$882,997, respectively, an increase of \$50,151 or 6%.

For the three months ended March 31, 2015, Milestone generated a gross profit of \$1,837,056 or 66%, as compared to a gross profit of \$1,737,837, or 66%, for the three months ended March 31, 2014. The total increase in gross profit dollars of \$99,219 is primarily due to an increase in revenue.

Selling, general and administrative expenses (“SG&A Expenses”) for the three months ended March 31, 2015 and 2014 were \$1,898,081 and \$1,392,869, respectively. This increase in expenses of \$505,212 is described in the following sections of this report. Milestone continues to focus on controlling expenses in all categories. However, beginning in the first quarter of 2015, Milestone began the process of building its marketing and sales efforts to increase revenues in the business sectors. As such, a large portion of the increase in SG&A expenses is in this area, as well as personnel costs. Marketing, including trade shows and related expenses, increased approximately \$30,000 in the first quarter of 2015 versus the same period in 2014. Payroll costs including bonus accruals increased approximately \$436,000 in the first quarter of 2015. Milestone expanded the number of marketing and executive staff in the USA and Internationally.

Additionally, our legal expenses increased for the quarter for general legal expenses and those expenses related to patents by a total of approximately \$109,000.

Research and development expenses for the three months ended March 31, 2015 and 2014 were \$10,118 and \$15,720, respectively, a decrease of \$5,602 or 36%, due to the software enhancement of the Wand *STA Instrument* in 2014.

The loss from operations for the three months ended March 31, 2015 was \$71,143 and income from operations for the three months ended March 31, 2014 was \$329,248. The \$400,391, or 122%, increase is explained above.

There is a loss on the Medical joint venture of \$450,160 (non cash) for the quarter ending March 31, 2015. There was a loss on the Education joint venture of \$4,214 for the quarter ending March 31, 2015. Milestone China has a gain on joint venture of \$96,674 for the quarter ending March 31, 2015. There was a loss on the Medical joint venture of \$130,523 for the quarter ending March 31, 2014. There was a loss on the Education joint venture of \$3,415 for the quarter ending March 31, 2014.

For the reasons explained above, net loss for the three months ended March 31, 2015 was \$427,634 and net income for the three months ended March 31, 2014 was \$194,834, respectively. The \$232,800, or 119%, increase in net loss is primarily a result of an increase in SG&A expenses of \$505,212 and a net increase of \$223,762 for the non-cash loss on the joint ventures and an increase in research and development expense of \$5,602.

Liquidity and Capital Resources

As of March 31, 2015, Milestone had cash and cash equivalents of \$9,331,405 and positive working capital of \$13,211,754.

The working capital at March 31, 2015 was \$13,211,754 as compared to the working capital at December 31, 2014 of \$13,147,256. The increase of \$64,497 in working capital was primarily attributable to a net current asset decrease of \$513,872 including, an increase in current accounts receivable of \$101,460, an increase in due from related party of \$184,589, a decrease in cash and cash equivalents of \$1,036,588 and an increase in inventory of \$268,914 offset by a net decrease in current liabilities of \$578,369.

Milestone continues to take positive steps to maintain adequate inventory levels and advances on contracts to maintain available inventory to meet our domestic and international sales requirements.

For the three months ended March 31, 2015, our net cash used in operating activities of \$681,191. This was attributable primarily to a net loss attributable to Milestone Scientific of \$419,375, net loss from noncontrolling interest of \$8,259 adjusted for noncash items of \$462,939 and changes in operating assets and liabilities of \$716,496.

Milestone has incurred annual operating losses and negative cash flows from operating activities since its inception, except for the year ended December 31, 2013, and positive cash flow in 2014. Milestone is actively pursuing the generation of positive cash flows from operating activities through increases in revenues based upon management's assessment of present contracts and current negotiations and reductions in operating expenses. With the \$10 million Private Placement (net \$9.4 million) in May 2014, Milestone believes that it does have sufficient cash reserves to meet all of its anticipated obligations for the next twelve months from March 31, 2015.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a smaller reporting company, Milestone is not required to provide the information required by this Item.

Item 4. Controls and Procedures

Milestone's management, including the Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the design and operation of Milestone's disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, Milestone's

Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of September 30, 2014 are effective to ensure that information required to be disclosed in the reports Milestone files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to Milestone's management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding disclosure.

There were no changes in Milestone's internal control over financial reporting identified in connection with the evaluation that occurred during Milestone's last fiscal quarter ended March 31, 2015 that have materially affected, or that are reasonably likely to materially affect, Milestone's internal controls over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

As a smaller reporting company, Milestone is not required to provide the information required by this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULT UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The following exhibits are filed herewith:

- 31.1 Chief Executive Officer Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.*
- 31.2 Chief Operating Officer Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.*
- 32.1 Chief Executive Officer Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.**
- 32.2 Chief Operating Officer Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.**
- 101.INS XBRL Instance Document. *
- 101.SCH XBRL Taxonomy Extension Schema Document.*
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document. *
- 101.LAB XBRL Taxonomy Extension Label Linkbase Document. *
- 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document. *
- 101.DEF XBRL Taxonomy Extension Definition Linkbase Document. *

*Filed herewith.

**Furnished, not filed, in accordance with Item 601(32)(ii) of Regulation-S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MILESTONE SCIENTIFIC INC.

/s/ Leonard Osser

Leonard Osser

Chief Executive Officer

(Principal Executive Officer)

/s/ Joseph D'Agostino

Joseph D'Agostino

Chief Operating Officer

Chief Financial Officer

(Principal Financial Officer)

Date: May 14, 2015

Rule 13a-14(a)/15d-14(a) Certification

I, Leonard Osser, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Milestone Scientific Inc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to Milestone is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, Milestone's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and, I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the Audit Committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 14, 2015

/s/ Leonard Osser
Leonard Osser
Chief Executive Officer
(Principal Executive Officer)

Rule 13a-14(a)/15d-14(a) Certification

I, Joseph D'Agostino, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Milestone Scientific Inc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to Milestone is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, Milestone's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and, I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the Audit Committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 14, 2015

/s/ Joseph D'Agostino
Joseph D'Agostino
Chief Operating Officer
Chief Financial Officer
(Principal Financial Officer)

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Milestone Scientific Inc (“Milestone”) on Form 10-Q for the period ending March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leonard Osser, Chief Executive Officer of Milestone, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone

Dated: March 14, 2015

/s/ Leonard Osser

Leonard Osser
Chief Executive Officer
(Principal Executive Officer)

A signed original of this certification has been provided to Milestone and will be retained by Milestone and furnished to the Securities and Exchange Commission or its staff upon request.

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Milestone Scientific Inc (“Milestone”) on Form 10-Q for the period ending March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph D’Agostino, Chief Financial Officer of Milestone, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone

Dated: May 14, 2015

/s/ Joseph D’Agostino

Joseph D’Agostino
Chief Operating Officer
Chief Financial Officer
(Principal Financial Officer)

A signed original of this certification has been provided to Milestone and will be retained by Milestone and furnished to the Securities and Exchange Commission or its staff upon request.